甘精胰岛素经皮超声导入与皮下注射的疗效比较  

The comparison of the therapeutic effect of insulin glargine given by percutaneous ultrasonic introduction versus subcutaneous injection

作　　者：华飞[1] 万静波[1] 唐暎[1] 万慧[1] 戈敏娟[1] 

机构地区：[1]苏州大学附属第三医院内分泌代谢科,常州市213003

出　　处：《中国糖尿病杂志》2011年第10期752-754,共3页Chinese Journal of Diabetes

基　　金：常州市社会发展科技计划项目(CS2008203)

摘　　要：目的探讨甘精胰岛素经皮超声导入的降糖效果。方法将43例T2DM患者随机分组,分别采用经皮超声导入甘精胰岛素和皮下注射甘精胰岛素两种不同方法控制血糖,自身前后交叉对照,评价经皮超声导入甘精胰岛素的降糖效果,比较不同给药方式所需的胰岛素剂量。结果甘精胰岛素采用经皮超声导入和皮下注射两种不同的给药方式,对空腹及餐后血糖的控制无统计学差异(P>0.05),不同给药方式所需甘精胰岛素剂量具有统计学差异(P<0.05)。结论经皮超声导入甘精胰岛素以及皮下注射甘精胰岛素两种给药方式均能有效控制血糖。在达到同样降糖目标的情况下,经皮超声导入所需甘精胰岛素剂量较皮下注射增多15%左右。Objective To investigate therapeutic effect of insulin glargine given by percutaneous ultrasonic introduction. Methods 43 type 2 diabetic patients were treated with insulin glargine by percutaneous ultrasonic introduction versus subcutaneous injection, therapeutic effect and dose-effect relationship were evaluated. Result No significant differences in fasting and postprandial blood glucose were found between the two medications before and after treatment（P〉0. 05）. But doses of insulin glargine were significantly different between two medications （P 〈 0. 05 ）. Conclusion Both percutaneous ultrasonic introduction and subcuaneous injection of glargine can effectively control blood glucose. For the same target of decreasing blood glucose, the doses of glargine given by percutaneous ultrasonic introduction are increased by 15% compared with subcuaneous injection.

关 键 词：糖尿病 2型 甘精胰岛素 经皮超声导入 

分 类 号：R587.1[医药卫生—内分泌]